M
MannKind Corporation (MNKD)
NGM – Real vaqt narxi. Valyuta: USD
3.28
-0.08 (-2.38%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
3.28
-0.08 (-2.38%)
Yopilishda: May 12, 2026, 4:00 PM EDT
MannKind Corporation, biofarmatsevtika kompaniyasi, surunkali kasalliklarni davolashga oid turli yechimlarni taqdim etishga qaratilgan. U diabet, o'pka gipertenziyasi va yurak etishmovchiligi hamda surunkali buyrak kasalligida suyuqlik ortishi kabi jiddiy tibbiy ehtiyojlarni qondiradigan davolash usullarini ishlab chiqadi va tijoratlashtiradi. U kattalardagi diabetni davolashda qondagi glyukozani nazorat qilishni yaxshilash uchun ishlatiladigan inhalatsiyalangan insulin Afrezza inhalatsion kukunini va kattalarda insulinin doimiy teri osti yuborishni ta'minlovchi V-Go kiyiladigan insulin yuborish moslamasini taklif etadi. Uning mahsulotlari orasida o'pka arteriyasi gipertenziyasi va interstitsial o'pka kasalligi bilan bog'liq o'pka gipertenziyasini davolash uchun Tyvaso DPI; surunkali yurak etishmovchiligi yoki surunkali buyrak kasalligi bo'lgan bemorlarda suyuqlik to'planishini davolash uchun furosemid in'ektsiyasi FUROSCIX mavjud. Kompaniyaning o'pka kasalliklari uchun davolash usullari qatorida idiopatik o'pka fibrozini davolash uchun nintedanibning quruq kukunli shakli bo'lgan MNKD-201 va MNKD-701 mavjud. Tyvaso DPIni ishlab chiqish, tartibga solish va tijoratlashtirish bo'yicha United Therapeutics Corporation bilan hamkorlik va litsenziya shartnomasi hamda o'pka fibrozini davolash uchun terapevtik vositani baholash bo'yicha Thirona bilan hamkorlik shartnomasi mavjud. MannKind Corporation 1991 yilda ro'yxatga olingan va shtab-kvartirasi Konnektikut shtatining Danberi shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Ajay Ahuja M.B.A., M.D. | Executive VP & Chief Medical Officer |
| Dr. David B. Thomson J.D., Ph.D. | Executive VP, General Counsel & Secretary |
| Dr. Michael E. Castagna Pharm.D. | CEO & Director |
| Dr. Stuart A. Tross Ph.D. | Chief People & Workplace Officer |
| Mr. Christopher B. Prentiss M.B.A. | Chief Financial Officer |
| Mr. Dominic Marasco R.Ph. | President of Endocrine Business Unit |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-06 | 10-Q | mnkd-20260331.htm |
| 2026-04-07 | DEF 14A | mnkd-20260407.htm |
| 2026-02-26 | 8-K | mnkd-20260226.htm |
| 2025-12-15 | 8-K/A | mnkd-20251007.htm |
| 2025-11-10 | 8-K | d25083d8k.htm |
| 2025-11-05 | 8-K | mnkd-20251105.htm |
| 2025-11-05 | 10-Q | mnkd-20250930.htm |
| 2025-10-09 | 8-K | d63266d8k.htm |
| 2025-10-07 | SC TO-T/A | d59433dsctota.htm |
| 2025-09-08 | SC TO-T | d34139dsctot.htm |
| Mr. Sanjay Singh M.B.A. | Executive Vice President of Technical Operations |